Want to see HK:8622 full AI Analyst Report?
Top Page
Huakang Biomedical Holdings Company Limited
(8622)
Select Model
Select Model
Rating:48Neutral
Price Target:
HK$0.23
▼(-45.71% Downside)
Action:Reiterated
Date:10/29/26
The score is held back primarily by weak financial performance—persistent losses and negative operating/free cash flow despite strong revenue growth and high gross margins. Technicals are moderately supportive with positive momentum above key short-term averages, but valuation is pressured by negative earnings (negative P/E) and no dividend support.
Positive Factors
Strong Revenue Growth
Rapid top-line expansion indicates that demand for the company’s products is growing and provides a broader revenue base for future operating improvement. If this growth persists, it could create greater scale and help the business convert its strong product economics into eventual profitability.
Negative Factors
Persistent Operating Losses
The company has not yet translated strong revenue growth and gross margins into sustainable profitability, with operating and net losses continuing across the reported periods. Persistent losses weaken internal funding capacity and make the durability of the business model dependent on achieving operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth
Rapid top-line expansion indicates that demand for the company’s products is growing and provides a broader revenue base for future operating improvement. If this growth persists, it could create greater scale and help the business convert its strong product economics into eventual profitability.
Read all positive factors
Huakang Biomedical Holdings Company Limited (8622) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$118.56M
Dividend YieldN/A
Average Volume (3M)249.87K
Price to Earnings (P/E)―
Beta (1Y)0.36
Revenue Growth30.60%
EPS Growth-6.86%
CountryHK
Employees101
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.01
Shares Outstanding515,472,000
10 Day Avg. Volume325,600
30 Day Avg. Volume249,866
Financial Highlights & Ratios
PEG Ratio-2.40
Price to Book (P/B)3.83
Price to Sales (P/S)6.93
P/FCF Ratio-59.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Huakang Biomedical Holdings Company Limited Business Overview & Revenue Model
Company Description
Huakang Biomedical Holdings Company Limited operates as an investment holding firm, primarily dedicated to the research, development, manufacturing, marketing, and distribution of in-vitro diagnostic (IVD) reagents within the People's Republic of ...
Huakang Biomedical Holdings Company Limited Financial Statement Overview
Summary
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
29
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 32.51M | 28.28M | 25.36M | 24.63M | 25.33M | 26.13M |
| Gross Profit | 19.92M | 17.77M | 17.07M | 16.09M | 16.91M | 16.46M |
| EBITDA | -2.54M | -4.17M | -1.68M | -2.55M | 188.00K | -852.00K |
| Net Income | -5.07M | -5.01M | -4.16M | -5.78M | -3.08M | -4.22M |
Balance Sheet | ||||||
| Total Assets | 66.21M | 66.64M | 65.22M | 65.31M | 66.40M | 67.06M |
| Cash, Cash Equivalents and Short-Term Investments | 39.23M | 41.96M | 36.49M | 32.94M | 33.30M | 36.21M |
| Total Debt | 7.66M | 4.96M | 4.08M | 5.14M | 1.88M | 1.78M |
| Total Liabilities | 17.09M | 15.46M | 11.17M | 14.30M | 9.88M | 9.36M |
| Stockholders Equity | 49.07M | 51.15M | 54.05M | 51.02M | 56.52M | 57.70M |
Cash Flow | ||||||
| Free Cash Flow | -7.21M | -3.29M | -5.05M | -1.55M | 475.00K | -4.71M |
| Operating Cash Flow | -6.10M | -2.21M | -3.06M | -48.00K | 1.29M | -2.38M |
| Investing Cash Flow | -1.88M | 2.32M | -4.42M | -1.15M | -6.11M | -2.06M |
| Financing Cash Flow | 5.13M | 4.78M | 6.30M | 1.02M | 2.32M | -1.37M |
Huakang Biomedical Holdings Company Limited Technical Analysis
Positive
0.42
Price Trends
0.18
Positive
0.18
Positive
0.26
Negative
Market Momentum
0.01
Negative
65.32
Neutral
79.50
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8622, the sentiment is Positive. The current price of 0.42 is above the 20-day moving average (MA) of 0.19, above the 50-day MA of 0.18, and above the 200-day MA of 0.26, indicating a neutral trend. The MACD of 0.01 indicates Negative momentum. The RSI at 65.32 is Neutral, neither overbought nor oversold. The STOCH value of 79.50 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8622.
Huakang Biomedical Holdings Company Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
61 Neutral | HK$53.38M | 13.29 | 1.02% | 121.95% | -18.16% | ― | |
54 Neutral | HK$147.90M | -0.13 | -154.56% | ― | -7.12% | -523.61% | |
53 Neutral | HK$401.18M | 100.00 | 0.34% | 84.69% | -8.30% | -44.44% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | HK$118.56M | -16.19 | -10.11% | ― | 30.60% | -6.86% | |
43 Neutral | HK$123.04M | -4.04 | -21.66% | 0.48% | -6.71% | 43.14% | |
42 Neutral | HK$191.35M | -2.73 | -14.55% | 1.13% | 12.89% | -2.56% |
* Healthcare Sector Average
HK:8622
Huakang Biomedical Holdings Company Limited
0.23
-0.24
-51.06%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.05
-0.04
-44.57%
HK:0455
Tianda Pharmaceuticals Ltd.
0.09
-0.05
-34.07%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.36
-0.10
-21.74%
HK:0911
Qianhai Health Holdings Ltd.
0.32
-0.03
-7.35%
HK:1498
PuraPharm Corp. Ltd.
0.23
-0.19
-45.24%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.